Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Attovia TherapeuticsATTO -2.38%8 3-Year EPS without NRI Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates ATTO with a GF Score™ of 8/100. The stock has 1 warning sign investors should review. Among 1,155 Biotechnology companies, Attovia Therapeutics ranks worse than 86580% on this metric.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
Attovia Therapeutics (NAS:ATTO) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Attovia Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
ATTO vs TBPH, ACRS, OLMA: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Attovia Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Attovia Therapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Attovia Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Attovia Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Attovia Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 0.00% mean?
Attovia Therapeutics (ATTO) has a 3-Year EPS without NRI Growth Rate of 0.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Attovia Therapeutics and its competitors. According to the industry distribution chart, Attovia Therapeutics ranks #999999 out of 1155 companies in the Biotechnology industry.
Is Attovia Therapeutics' 3-Year EPS without NRI Growth Rate too high?
Attovia Therapeutics' current 3-Year EPS without NRI Growth Rate is 0.00%. Based on the distribution chart, Attovia Therapeutics ranks #999999 out of 1155 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Attovia Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Attovia Therapeutics' 3-Year EPS without NRI Growth Rate compare to TBPH and ACRS?
According to the Biotechnology industry distribution chart, Attovia Therapeutics ranks #999999 out of 1155 companies for 3-Year EPS without NRI Growth Rate. This places Attovia Therapeutics in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.00, based on 1,155 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Attovia Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Attovia Therapeutics's current 3-Year EPS without NRI Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Attovia Therapeutics stock overvalued right now?
Attovia Therapeutics (ATTO) has a current 3-Year EPS without NRI Growth Rate of 0.00%. The current 3-Year EPS without NRI Growth Rate is 0.00%. Attovia Therapeutics' overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Attovia Therapeutics (ATTO), the current 3-Year EPS without NRI Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
8GF Score
Get the complete analysis for ATTO
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATTO has been successfully added to your 
